New leukaemic targeted treatments : Implication of the clinical laboratory
- At: 2008 FIP Congress in Basel (Switzerland)
- Type: Presentation
- By: DEMAS, Veronique (Hopitaux de Toulouse, Toulouse, France)
In recent years, the focus of anticancer drug development has shifted from conventional cytotoxic drugs that directly affect processes such as DNA synthesis to targeted agents that modulate protein functions such as tyrosine kinase activity, frequently constitutively active in cancer (like imatinib), surface expression (like rituximab, an.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.